Evidence map›Paper›PMID 30809980›Full record

ReviewAnnals of laboratory medicine2019

The Platelet-to-Lymphocyte Ratio as an Inflammatory Marker in Rheumatic Diseases.

Armen Yuri Gasparyan, Lilit Ayvazyan, Ulzhan Mukanova, Marlen Yessirkepov, George D Kitas

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annals of laboratory medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 327 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
327citing papers in PubMed, 10 pooled it
24.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

327 citing papers in PubMed, 10 syntheses or guidelines pooled it, 590 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

267 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 3 countries.

Armen Yuri GasparyanDepartments of Rheumatology and Research and Development, Dudley Group NHS Foundation Trust (Teaching Trust of the University of Birmingham, UK), Russells Hall Hospital, Dudley, West Midlands, UK. a.gasparyan@gmail.com.ORCID https://orcid.org/0000-0001-8749-6018
Lilit AyvazyanDepartment of Medical Chemistry, Yerevan State Medical University, Yerevan, Armenia.ORCID https://orcid.org/0000-0002-9797-4770
Ulzhan MukanovaDepartment of Surgical Disciplines, South Kazakhstan Medical Academy, Shymkent, Kazakhstan.ORCID https://orcid.org/0000-0001-9343-2934
Marlen YessirkepovDepartment of Biology and Biochemistry, South Kazakhstan Medical Academy, Shymkent, Kazakhstan.ORCID https://orcid.org/0000-0003-2511-6918
George D KitasDepartments of Rheumatology and Research and Development, Dudley Group NHS Foundation Trust (Teaching Trust of the University of Birmingham, UK), Russells Hall Hospital, Dudley, West Midlands, UK.ORCID https://orcid.org/0000-0002-0828-6176
Russells Hall Hospital · GBSouth Kazakhstan Medical Academy · KZYerevan State Medical University · AM

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The platelet-to-lymphocyte ratio (PLR) has emerged as an informative marker revealing shifts in platelet and lymphocyte counts due to acute inflammatory and prothrombotic states. PLR has been extensively examined in neoplastic diseases accompanied by immune suppression and thrombosis, which can be predicted by combined blood cell counts and their ratios. Several large observational studies have demonstrated the value of shifts in PLR in evaluating the severity of systemic inflammation and predicting infections and other comorbidities, in inflammatory rheumatic diseases. The value of PLR as an inflammatory marker increases when its fluctuations are interpreted along with other complementary hematologic indices, particularly the neutrophil-to-lymphocyte ratio (NLR), which provides additional information about the disease activity, presence of neutrophilic inflammation, infectious complications, and severe organ damage in systemic lupus erythematosus. PLR and NLR have high predictive value in rheumatic diseases with predominantly neutrophilic inflammation (e.g., Behçet disease and familial Mediterranean fever). High PLR, along with elevated platelet count, is potentially useful in diagnosing some systemic vasculitides, particularly giant-cell arteritis. A few longitudinal studies on rheumatic diseases have demonstrated a decrease in PLR in response to anti-inflammatory therapies. The main limitations of PLR studies are preanalytical faults, inadequate standardization of laboratory measurements, and inappropriate subject selection. Nonetheless, accumulating evidence suggests that PLR can provide valuable information to clinicians who encounter multisystem manifestations of rheumatic diseases, which are reflected in shifts in platelet, lymphocyte, neutrophil, or monocyte counts. Interpretation of PLR combined with complementary hematologic indices is advisable to more accurately diagnose inflammatory rheumatic diseases and predict related comorbidities.

Indexed as

Anti-Inflammatory AgentsBiomarkersBlood PlateletsGiant Cell ArteritisHumansLymphocytesNeoplasmsRheumatic DiseasesAnti-Inflammatory AgentsBiomarkersInflammationLymphocyte countMarkersNeutrophil countPlatelet countPlatelet-to-lymphocyte ratioRheumatic diseases

Identifiers

PMID30809980
PMCPMC6400713
OpenAlexW2917958408

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.